Adaptive Biotechnologies director granted 15,625 shares

OWEN KATEY EINTERZ reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/06/2026 - 07:10 PM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

OWEN KATEY EINTERZ reported acquisition or exercise transactions in this Form 4 filing.

Adaptive Biotechnologies Corp director Katey Einterz Owen received an equity award of 15,625 shares of Common Stock on March 4, 2026. The shares were granted at a price of $0.00 per share, indicating a stock award rather than an open‑market purchase. Following this grant, her directly held Common Stock increased to 88,254 shares, reflecting her updated ownership position as a company director.

Insider Trade Summary

Grant/Award: 15,625 shares

Grant/Award 1 txn

Insider OWEN KATEY EINTERZ

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,625	$0.00	$0.00

Holdings After Transaction: Common Stock — 88,254 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ADPT director Katey Einterz Owen report on this Form 4?

Director Katey Einterz Owen reported receiving a stock award of 15,625 shares of Adaptive Biotechnologies Common Stock. The award was recorded on March 4, 2026 and classified as a grant or other acquisition rather than a market purchase or sale.

How many Adaptive Biotechnologies (ADPT) shares does Katey Einterz Owen hold after this grant?

After the reported stock award, Katey Einterz Owen directly holds 88,254 shares of Adaptive Biotechnologies Common Stock. This figure reflects her ownership position immediately following the March 4, 2026 equity grant of 15,625 shares reported on the Form 4.

Was cash paid for the ADPT shares granted to director Katey Einterz Owen?

No cash was paid for the shares in this transaction; the reported price per share is $0.00. This indicates the 15,625 Adaptive Biotechnologies shares were granted as an equity award rather than purchased in the open market or through a cash transaction.

How is the Form 4 transaction for ADPT classified in terms of direction?

The Form 4 classifies the transaction as an acquisition, specifically a grant or award of Common Stock. It is coded as transaction type “A,” meaning Katey Einterz Owen increased her direct holdings in Adaptive Biotechnologies through a non‑derivative equity grant.

Does the ADPT Form 4 involve derivative securities or only common stock?

The reported transaction involves only non‑derivative securities, specifically Common Stock of Adaptive Biotechnologies. The filing lists one transaction: a grant of 15,625 shares of Common Stock, with no options, warrants, or other derivative instruments disclosed in this particular report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OWEN KATEY EINTERZ

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

98109

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/04/2026		A		15,625	A	$0	88,254	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Katey Einterz Owen by Kyle Piskel, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR